Dynavax Technologies (NASDAQ:DVAX) Issues Earnings Results, Meets Expectations

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported $0.05 earnings per share for the quarter, hitting the consensus estimate of $0.05, Zacks reports. The company had revenue of $72.03 million for the quarter, compared to analysts' expectations of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%.

Dynavax Technologies Trading Up 0.7 %

DVAX traded up $0.09 on Monday, hitting $13.42. 2,026,956 shares of the company were exchanged, compared to its average volume of 1,843,953. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The firm has a fifty day simple moving average of $12.83 and a two-hundred day simple moving average of $12.06. The stock has a market capitalization of $1.76 billion, a PE ratio of 74.56 and a beta of 1.32. Dynavax Technologies has a 12 month low of $9.74 and a 12 month high of $14.05.

Wall Street Analyst Weigh In

DVAX has been the topic of several research analyst reports. William Blair restated an "outperform" rating on shares of Dynavax Technologies in a research report on Friday. The Goldman Sachs Group cut shares of Dynavax Technologies from a "neutral" rating to a "sell" rating and decreased their price objective for the stock from $15.00 to $12.00 in a research report on Tuesday, February 11th. StockNews.com cut shares of Dynavax Technologies from a "buy" rating to a "hold" rating in a research report on Wednesday, February 12th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $31.00 price objective on shares of Dynavax Technologies in a research note on Friday.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.